T1	p 81 136	postmenopausal breast cancer survivors with bone loss :
T2	p 381 434	223 postmenopausal breast cancer survivors . Subjects
T3	p 584 628	postmenopausal breast cancer survivors ( BCS
T4	p 858 859	2
T5	p 862 870	subjects
T6	p 923 927	ST )
T7	p 1014 1015	3
T8	p 1111 1135	Postmenopausal BCS ( 223
T9	p 2227 2245	postmenopausal BCS
T10	i 20 35	weight training
T11	i 227 252	weight training exercises
T12	i 283 294	risedronate
T13	i 297 304	calcium
T14	i 307 320	and vitamin D
T15	i 666 677	risedronate
T16	i 680 687	calcium
T17	i 694 703	vitamin D
T18	i 896 937	strength/weight training ( ST ) exercises
T19	i 1164 1207	exercise plus medication or medication only
T20	i 1251 1259	1,200 mg
T21	i 1263 1402	calcium and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the exercise group additionally had ST exercises twice weekly .
T22	i 2165 2199	Strength/weight training exercises
T23	o 39 77	bone mineral density and bone turnover
T24	o 349 377	bone mineral density ( BMD )
T25	o 498 501	BMD
T26	o 531 536	BMD .
T27	o 718 746	bone mineral density ( BMD )
T28	o 840 853	bone turnover
T29	o 963 970	BMD and
T30	o 992 1011	bone turnover ; and
T31	o 1097 1100	BMD
T32	o 1375 1387	ST exercises
T33	o 1507 1510	BMD
T34	o 1518 1527	total hip
T35	o 1591 1601	Alkphase B
T36	o 1617 1626	serum NTx
T37	o 1691 1697	in BMD
T38	o 1705 1717	femoral neck
T39	o 1857 1866	Serum NTx
T40	o 1891 1923	changes in BMD and bone turnover
T41	o 1929 1937	exercise
T42	o 2036 2039	BMD
T43	o 2212 2223	loss of BMD